TikoMed Platform Boosts Regenerative Stem Cell Therapy Outcomes
Executive Summary
TikoMed founder and CEO Adam Bruce talks to Scrip during BIO-Europe Spring about how the company's IBsolvMIR platform has the potential to improve the viability of cells prior to transplantation.